SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Analyst sentiment is moderately positive: Eleven brokerages give SAB Biotherapeutics a consensus “Moderate Buy” rating, with nine buys, one hold and one sell. The average 12-month price target is $12.00, substantially above the reported $3.78 opening price.
• The stock remains financially unprofitable but well-capitalized: SAB reported a quarterly loss of $0.28 per share, in line with estimates, while analysts expect a full-year loss of $1.21 per share. The company has a strong quick and current ratio of 9.22 and minimal debt.
• Institutional interest has increased: Several hedge funds initiated or expanded positions, including Perceptive Advisors, which increased its holdings by 700.8%. Institutional investors collectively own 7.82% of the company.

SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) has earned an average recommendation of "Moderate Buy" from the eleven brokerages that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and nine have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $12.00.

SABS has been the topic of several research reports. Rodman & Renshaw restated a "buy" rating and set a $13.00 price objective on shares of SAB Biotherapeutics in a report on Monday, May 11th. Barclays initiated coverage on shares of SAB Biotherapeutics in a report on Wednesday, June 24th. They set an "overweight" rating and a $13.00 price objective for the company. Chardan Capital boosted their target price on shares of SAB Biotherapeutics from $14.00 to $16.00 and gave the stock a "buy" rating in a research report on Wednesday, June 17th. Citigroup assumed coverage on shares of SAB Biotherapeutics in a research report on Friday, May 22nd. They issued a "buy" rating and a $11.00 price target on the stock. Finally, Weiss Ratings downgraded SAB Biotherapeutics from a "sell (d+)" rating to a "sell (e+)" rating in a research note on Thursday.

SAB Biotherapeutics Trading Down 3.1%

NASDAQ SABS opened at $3.78 on Tuesday. The company has a market cap of $343.94 million, a price-to-earnings ratio of -2.91 and a beta of 0.53. SAB Biotherapeutics has a 52 week low of $1.85 and a 52 week high of $5.15. The business has a 50 day moving average price of $3.69 and a 200-day moving average price of $3.83. The company has a quick ratio of 9.22, a current ratio of 9.22 and a debt-to-equity ratio of 0.01.

SAB Biotherapeutics (NASDAQ:SABS - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.28) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.28). As a group, equities analysts expect that SAB Biotherapeutics will post -1.21 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Vivo Capital LLC purchased a new stake in SAB Biotherapeutics in the 3rd quarter valued at $22,954,000. Perceptive Advisors LLC boosted its holdings in SAB Biotherapeutics by 700.8% during the 1st quarter. Perceptive Advisors LLC now owns 6,431,743 shares of the company's stock worth $24,634,000 after acquiring an additional 5,628,533 shares during the last quarter. RA Capital Management L.P. purchased a new position in SAB Biotherapeutics during the 3rd quarter worth $8,847,000. Woodline Partners LP bought a new stake in shares of SAB Biotherapeutics in the 3rd quarter worth $5,730,000. Finally, Spruce Street Capital LP bought a new stake in shares of SAB Biotherapeutics in the 4th quarter worth $8,222,000. Hedge funds and other institutional investors own 7.82% of the company's stock.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company's proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company's lead programs are directed primarily at infectious diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source